Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection

Table 1 Clinical and demographic features of patients included in the study

	SARS-CoV2 + (31)	SARS-CoV2 − (18)	p value
Age	66.7 ± 14.4	67.1 ± 17.5	0.372
Sex
Males	23 (74.2%)	11 (61.1%)	0.357
Females	8 (25.8%)	7 (38.9%)	0.357
Gastrointestinal symptoms	13 (41.9%)	5 (27.8%)	0.249
Respiratory failure*	22 (73.3%)	6 (33.3%)	0.012
ARDS categories^a
III	14 (63.6%)	5 (83.3%)
II	7 (31.8%)	1 (16.7%)
I	1 (4.5%)	0
History of chronic lung disease	4 (12.9%)	3 (16.7%)	0.512
Treatment during hospitalization
Antibiotics	22 (71%)	18 (94.7%)	0.05
Antivirals	27 (90%)	3 (16.7%)	0.00
Hydroxychloroquine	29 (93.5%)	2 (10.5%)	0.017
Anti-IL-6 receptor monoclonal antibodies	8 (25.8%)	0

Numeric variables are reported as mean ± standard deviation, categorical ones as frequencies and percentages
*Number of patients with respiratory failure during hospitalization (PaO₂/FiO₂ ratio < 300)
Significance was evaluated by Wilcoxon signed rank test and chi-square test (IBM SPSS Statistics)
SARS‑CoV‑2 severe acute respiratory syndrome coronavirus 2; IL interleukin
^aIII PaO₂/FiO₂ ratio 200–300, II PaO2/FiO2 ratio 100–200, I PaO2/FiO2 ratio < 100

ISSN: 1757-4749